MoonLake Investors Face Dec. 15 Deadline To Seek Lead Role in Securities Suit

Overview

• Notices from multiple firms, including the Law Offices of Howard G. Smith and The Rosen Law Firm, urge MoonLake shareholders to move for lead‑plaintiff appointment by December 15, 2025.
• Purchasers of MoonLake common stock from March 10, 2024 through September 29, 2025 are within the putative class period identified in the complaints.
• The filings allege MoonLake made false or misleading statements about sonelokimab’s Nanobody advantages, asserting SLK and BIMZELX target the same cytokines (IL‑17A and IL‑17F) and that claimed tissue penetration would not yield superior efficacy.
• The case cites MoonLake’s September 28, 2025 week‑16 VELA results and a subsequent 89.9% share price drop to $6.24 on September 29 as the event that revealed the disputed information.
• No class has been certified, so investors are not represented unless they retain counsel, and any investor may seek to be lead plaintiff by the court‑imposed deadline.